Skip to main content
. 2022 Dec 19;24(1):e56033. doi: 10.15252/embr.202256033

Figure 1. Systemic antibiotics currently approved and marketed in the United States without antitubercular treatment.

Figure 1

Clock‐wise from the top: natural product‐derived antibiotics (79%): cephalosporins (24), penicillins (14), aminoglycosides (8), tetracyclins (5), glycopeptides (4), rifamycins (3), macrolides (3), carbapenems (3), polypeptides (2), amphenicol (1), daptomycin (1), fosfomycin (1)*, lincosamid (1), monobactams (1), nitroheterocycles** (1), pleuromutilins (1), streptogramins (1); antibiotics with synthetic origin (21%): sulfonamides (9), fluoroquinolones (7), oxazolidinones (2), aminopyrimidine (1), nitroheterocycles** (1). *not yet approved in the United States (Werth, 2022), **The nitroheterocyle metronidazole is derived from a natural product whereas nitroheterocycle nitrofurantoin is of synthetic origin. Source data are in Appendix Table S1.Source data are available online for this figure.